CLOs on the Move


 
Let’s operate. We prioritize you, so you can prioritize patients. Trusted brands like Quill, Sharpoint, and Tachosil.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

MnPharm

MNPHARM SBC is a manufacturer of recombinant regenerative proteins using a proprietary method called molecular farming. We supply these proteins to researchers working on therapeutic development. Our plant based expression method only takes 6 to 8 days. We offer faster production and lower cost resulting in rapid therapeutic development.

CRB

CRB is a Oreland, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

HEXO Corporation

HEXO is an award-winning licensed producer of innovative products for the global cannabis market. HEXO serves the Canadian recreational market with a brand portfolio including HEXO, UP Cannabis, Original Stash, Bake Sale, Namaste, and REUP brands, and the medical market in Canada, Israel and Malta. The Company also serves the Colorado market through its Powered by HEXO® strategy and Truss CBD USA, a joint venture with Molson Coors. In the event that the previously announced transactions to acquire 48North and Redecan close, HEXO expects to be the number one cannabis products company in Canada by recreational market share.

Provectus Biopharmaceuticals

Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus` investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers.

Oramed

Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).